Each month, the OVPR highlights the past month’s sponsored research funding awarded to Tufts’ investigators, including both a list of funded awards and one or more featured project abstracts.
You can download the list of April’s awardees by clicking the button below. In April, Tufts researchers received 42 awards for extramural funding from federal, foundation, and corporate sponsors.
To submit a recent award to be highlighted, please use the "nominate a project" button below.
This month our featured abstracts highlights two National Institutes of Health Awards.
The first, the Tufts Clinical and Translational Science Institute (CTSI), is the third round of successful funding for the CTSI, which accelerates the translation of research into clinical use, medical practice, and health impact. Harry P. Selker, MD, MSPH, Tufts CTSI Dean and Principal Investigator, leads the award in collaboration with Karen Freund, MD, MPH, Tufts CTSI Director of the Faculty Career Development (KL2) Program, and David Kent, MD, MSc, CTSI Director of the Research Fellowship (TL1) Program and the Clinical and Translational Science Graduate Program.
The second highlight features Evangelos Papathanasiou, Assistant Professor in Periodontology, who has been awarded a Mentored Clinical Scientist Research Career Development (K08) to investigate wound healing under the guidance of Carroll Ann Trotman, Professor and Chair of Orthodontics, and Tom Van Dyke of the Forsyth Institute.
PIs: Harry Selker, Karen Freund, David Kent
Title: Tufts Clinical and Translational Science Institute (CTSI)
Abstract: This award, the third round of funding for the Tufts CTSI (https://www.tuftsctsi.org/), was recently featured by Tufts Now. To learn more about this award, please use the following link to visit that article: http://now.tufts.edu/news-releases/tufts-clinical-and-translational-science-institute-ctsi-receives-56-million-national
PI: Evangelos Papathanasiou
Title: Specialized Pro-resolving Mediators (SPMs) & scar tissue formation after cleft-lip surgical repair
Abstract: Cleft lip with or without cleft palate is the most common congenital malformation of the head and the third most common birth defect. The impact of cleft lip on quality of life for the child and the family can be severe, affecting the child's appearance, speech, hearing, growth, psychosocial well-being and social integration. Surgical repair of the lip is the only treatment and is usually performed during the first year of life. However, hypertrophic scar (HTS) formation is a frequent postoperative complication that impairs soft tissue form, function or movement and multiple lip revision surgeries are required throughout childhood for optimum esthetics and function. Uncontrolled and prolonged inflammation plays a major role in tissue injury, tissue scarring, and fibrosis. There is a critical need for new therapeutic regimens to help patients prone to scar tissue formation after lip repair and revision surgeries. The objective of this proposal is to evaluate a new approach to promote wound healing and limit scarring based on endogenous specialized pro-resolving lipid mediators (SPMs), termed Resolvins. The overarching hypothesis is that resolvins applied topically will minimize hypertrophic scarring after cleft lip repair surgery by promoting resolution of inflammation. The problem will be approached in two phases: the actions of resolvins in prevention of lip scarring will be determined in an animal model, followed by initial human studies that will generate hypotheses for future human clinical application. The specific aims are: 1a) Characterize the inflammatory/lipid mediator profile of hypertrophic scars after cleft lip defect re- pair in an FDA approved animal model; 1b) Using the rabbit model, we will determine the impact of a well characterized specialized pro-resolving lipid mediator (RvE1) on scar formation and inflammatory/lipid media- tors in wound healing after cleft lip defect repair; 2) Characterize the human inflammatory/lipid mediator profile of cleft lip wound exudate and correlate it with scarring in patients undergoing cleft lip repair surgery.